Form 8-K - Current report:
SEC Accession No. 0001628280-22-000440
Filing Date
2022-01-06
Accepted
2022-01-06 17:30:34
Documents
5
Period of Report
2022-01-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K asancusopressreleasex1422.htm 8-K 34465
2 EX-2.1 finalforexecutionkkuscipde.htm EX-2.1 201895
3 EX-99.1 ex991sancusopressrelease-j.htm EX-99.1 27823
4 image_0a.jpg GRAPHIC 78510
5 image_1a.jpg GRAPHIC 41830
  Complete submission text file 0001628280-22-000440.txt   431349
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 22515711
SIC: 2834 Pharmaceutical Preparations